WallStreetZenWallStreetZen
Analyst Ranking
Bottom 6%
#4169 out of 4426 analysts
Average Return
-12.84%
Win Rate
38%8 out of 21
Risk vs Reward
Poor
Good

Matt Hewitt's 5 best and worst ratings

Name / TickerGain/LossEntry PriceExit PricePeriodRating
Simulations Plus IncSLP
+142.31%$31.01$75.14
2020-01-06 -
2021-01-06
Buy
Ligand Pharmaceuticals IncLGND
+63.13%$80.55$131.40
2020-10-21 -
2021-10-20
Buy
Vocera Communications IncVCRA
+30.13%$31.40$40.86
2020-07-28 -
2021-07-27
Buy
Omniab IncOABI
+27.42%$3.83$4.88
2023-04-13 -
2023-12-08
Buy
Apollo Endosurgery IncAPEN
+22.07%$6.75$8.24
2017-07-24 -
2018-07-24
Buy

Matt Hewitt Analyst Color

Get additional color on Matt Hewitt's coverage of popular stocks

Matt Hewitt's Stock Coverage

Name / TickerNo. RatingsRatingPrice TargetUpside/DownsideActionDate
Avid Bioservices IncCDMO
3Buy$16.00+244.83%Maintains
2 days ago
Maxcyte IncMXCT
1Buy$7.00+44.33%Initiates Coverage On
11 days ago
Biolife Solutions IncBLFS
2Buy$23.00+73.45%Maintains
4 months ago
Repligen CorpRGEN
2Buy$200.00+25.57%Maintains
4 months ago
Omniab IncOABI
1Buy$10.00+104.92%Initiates Coverage On
8 months ago
Surgalign Holdings IncSRGAQ
2Hold$2.00+992.90%Maintains
8 months ago
Simulations Plus IncSLP
4Buy$60.00N/AMaintains
a year ago
Science 37 Holdings IncSNCE
1Buy$200.00N/AInitiates Coverage On
2 years ago
Cynergistek IncCTEK
1Hold$1.25N/ADowngrades
2 years ago
Teladoc Health IncTDOC
4Hold$30.00N/AMaintains
2 years ago
Ispecimen IncISPC
1Buy$20.00N/AInitiates Coverage On
2 years ago
Omnicell IncOMCL
1Buy$205.00N/AMaintains
2 years ago
Inotiv IncNOTV
1Buy$45.00N/AInitiates Coverage On
2 years ago
Schrodinger IncSDGR
1Buy$85.00N/AInitiates Coverage On
3 years ago
Ligand Pharmaceuticals IncLGND
1Buy$195.00N/AMaintains
3 years ago
Vocera Communications IncVCRA
1Buy$30.00N/AUpgrades
3 years ago
Apollo Endosurgery IncAPEN
1Buy$11.00N/AInitiates Coverage On
6 years ago
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.